Stock Track | Revolution Medicines Soars 16.21% in Pre-Market on Breakthrough Pancreatic Cancer Trial Results

Stock Track06-01

Revolution Medicines, Inc. (NASDAQ:RVMD) experienced a significant pre-market surge of 16.21% following the release of landmark clinical trial data for its lead drug candidate.

The sharp increase was driven by detailed results from the global Phase 3 RASolute 302 clinical trial presented at the ASCO annual meeting, which evaluated daraxonrasib for metastatic pancreatic ductal adenocarcinoma. The data showed that daraxonrasib more than doubled median overall survival to 13.2 months compared to 6.7 months for standard chemotherapy, while also reducing the risk of death by 60%.

These breakthrough results represent a potential paradigm shift in pancreatic cancer treatment, where RAS mutations are highly prevalent but targeted therapies have been scarce. The positive data has generated substantial market optimism, with analysts responding by reiterating Buy ratings and raising price targets based on the strong pivotal results and launch prospects for daraxonrasib.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101539390?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 16:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101539390","market":"hk","top_or_hot":-1,"title":"Stock Track | Revolution Medicines Soars 16.21% in Pre-Market on Breakthrough Pancreatic Cancer Trial Results","media":"Stock Track","content":"<p>Revolution Medicines, Inc. (NASDAQ:RVMD) experienced a significant pre-market surge of 16.21% following the release of landmark clinical trial data for its lead drug candidate.</p><p>The sharp increase was driven by detailed results from the global Phase 3 RASolute 302 clinical trial presented at the ASCO annual meeting, which evaluated daraxonrasib for metastatic pancreatic ductal adenocarcinoma. The data showed that daraxonrasib more than doubled median overall survival to 13.2 months compared to 6.7 months for standard chemotherapy, while also reducing the risk of death by 60%.</p><p>These breakthrough results represent a potential paradigm shift in pancreatic cancer treatment, where RAS mutations are highly prevalent but targeted therapies have been scarce. The positive data has generated substantial market optimism, with analysts responding by reiterating Buy ratings and raising price targets based on the strong pivotal results and launch prospects for daraxonrasib.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Revolution Medicines Soars 16.21% in Pre-Market on Breakthrough Pancreatic Cancer Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Revolution Medicines Soars 16.21% in Pre-Market on Breakthrough Pancreatic Cancer Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-01 16:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Revolution Medicines, Inc. (NASDAQ:RVMD) experienced a significant pre-market surge of 16.21% following the release of landmark clinical trial data for its lead drug candidate.</p><p>The sharp increase was driven by detailed results from the global Phase 3 RASolute 302 clinical trial presented at the ASCO annual meeting, which evaluated daraxonrasib for metastatic pancreatic ductal adenocarcinoma. The data showed that daraxonrasib more than doubled median overall survival to 13.2 months compared to 6.7 months for standard chemotherapy, while also reducing the risk of death by 60%.</p><p>These breakthrough results represent a potential paradigm shift in pancreatic cancer treatment, where RAS mutations are highly prevalent but targeted therapies have been scarce. The positive data has generated substantial market optimism, with analysts responding by reiterating Buy ratings and raising price targets based on the strong pivotal results and launch prospects for daraxonrasib.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVMD","symbol_name":"Revolution Medicines, Inc.","start_time":0,"source_url":"","article_id":"1101539390","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101539390","pubTimestamp":1780301251,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Revolution Medicines, Inc. (NASDAQ:RVMD) experienced a significant pre-market surge of 16.21% following the release of landmark clinical trial data for its lead drug candidate.The sharp increase was...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVMD":"Revolution Medicines, Inc."},"translate_title":"股票追踪|Revolution Medicines盘前大涨16.21%胰腺癌试验结果取得突破性进展","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1},"content_text":"Revolution Medicines, Inc. (NASDAQ:RVMD) experienced a significant pre-market surge of 16.21% following the release of landmark clinical trial data for its lead drug candidate.The sharp increase was driven by detailed results from the global Phase 3 RASolute 302 clinical trial presented at the ASCO annual meeting, which evaluated daraxonrasib for metastatic pancreatic ductal adenocarcinoma. The data showed that daraxonrasib more than doubled median overall survival to 13.2 months compared to 6.7 months for standard chemotherapy, while also reducing the risk of death by 60%.These breakthrough results represent a potential paradigm shift in pancreatic cancer treatment, where RAS mutations are highly prevalent but targeted therapies have been scarce. The positive data has generated substantial market optimism, with analysts responding by reiterating Buy ratings and raising price targets based on the strong pivotal results and launch prospects for daraxonrasib.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101539390","isCrawlerRequest":true}